Royalty Obligation Sample Clauses

Royalty Obligation. As a material inducement and consideration to Broncus to grant the sublicense to Asthmatx pursuant to Section 2, for so long as Broncus has any obligation to pay royalties to Ntero under the Ntero License Agreement, Asthmatx shall pay to Broncus, with respect to any Asthmatx Net Sales in such calendar quarter, the full amount payable by Broncus to Ntero with respect to such Asthmatx Net Sales under the terms of the Ntero License Agreement. As of the Effective Date, the amount payable by Broncus with respect to such Asthmatx Net Sales is: (a) in the event that the relevant Ntero Licensed Product performs the Primary Function (as that term is defined in the Ntero License Agreement) but does not perform any other material function, ***** percent (*****%) of the aggregate Asthmatx Net Sales of such Ntero Licensed Product; and (b) in the event that a Ntero Licensed Product performs other material functions in addition to the Primary Function (as that term is defined in the Ntero License Agreement), ***** percent (*****%) of the aggregate Asthmatx Net Sales of such Ntero Licensed Product.

Royalty Obligation. Subject to Section 4.2, with respect to each Royalty-Bearing Product, Celldex shall pay to Medarex a royalty on annual (based on a calendar year) aggregate worldwide Net Sales of Royalty-Bearing Products on a Royalty-Bearing Product-by-Royalty-Bearing Product basis as follows:

Royalty Obligation. Licensee acknowledges that the termination of this Agreement by either party for any reason shall not absolve Licensee of its payment and other obligations under Section 4.1(b).

Royalty Obligation. (a) As from the Commencement Date, for each Quarter in which any Product is produced and sold, removed or otherwise disposed of, the Payer agrees to pay to the Payees the Royalty calculated in accordance with this deed. (b) The obligation to pay the Royalty accrues upon the receipt by a Payer of revenue received from the sale or other disposal of Products, or as otherwise set out in this deed.

Royalty Obligation. At the conclusion of the Sell-Off Period, SSG’s obligation to pay Equilink any future royalty, including the Guaranteed Minimum Annual Royalty, shall terminate, provided, however, this provision will not affect SSG’s obligation to pay Equilink any royalty due and owing as of the end of the Sell-Off Period. If the Sell-Off Period ends at any time other than the end of a Royalty Year, the Guaranteed Annual Minimum Royalty for that Royalty Year will be pro-rated based on a fraction, the numerator of which is the number of months of the Royalty Year that occurred prior to the end of the Sell-Off Period and the denominator of which will be 12.

Royalty Obligation. In the event that CK commercializes a CK Product independently of GSK (i.e., in the case where GSK does not exercise the CK Product Option), then in such case CK shall pay to GSK a royalty on sales of such CK Product by CK, its Affiliates and Sublicensees, in an amount to be reasonably established by the Parties, based on the extent to which GSK has [*] under this Agreement, and/or has provided [*] to [*], that [*] the research, development or commercialization of such CK Product. In the event the Parties are not able to agree upon such royalty, then upon request by either Party, such amount shall be determined in accordance with Section 12.3.1 below. It is understood that, in connection with establishing the applicable royalty, the ancillary terms of such royalty, such as the term for which such royalties are due, the definition of CK's net sales, royalty reporting, audit rights, [*] (such as those in Section [*] below) and the like will also be established, which terms will be no less favorable to CK than the corresponding terms of this Agreement. Notwithstanding the foregoing, in no event shall the royalty to be paid to GSK exceed the following amounts, based on the stage of the CK Product at the time the relevant Mitotic Kinesin Target became a CK Target (the "Reversion Stage"), as reflected in the table below: REVERSION STAGE [*] ROYALTY --------------- ----------- [*] [*]% [*] [*]% [*] [*]% [*] [*]% [*] [*]% * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

Royalty Obligation. In consideration of the sublicense and license rights granted to Abbott pursuant to Sections 6.1 and 6.2, Abbott shall pay to Rubicon royalties based on Net Sales in countries where a Valid Claim exists. The applicable royalty rate is as follows: (a) Five percent (5%) on the first One Hundred Million Dollars ($ 100,000,000) of cumulative Net Sales; (b) Six percent (6%) on the Second One Hundred Million Dollars ($100,000,000) of cumulative Net Sales; and

Royalty Obligation. The obligation to pay royalties hereunder will arise upon the sale by Xtent, its Affiliates or its Sublicensees, if any, to third parties, including, without limitation, sales to Occam in its capacity as a distributor of Xtent. Sublicense Royalties due will be deemed to accrue when Royalty Bearing Products are sold to such un-Affiliated third party, regardless of when payment has been received therefor. The obligation to pay royalties to Occam will be imposed only once with respect to the same unit of Royalty Bearing Product.

Royalty Obligation. (a) The Grantor hereby grants and conveys the Royalty to the Royalty Holder. (b) The Royalty shall bind the Grantor and its successors and assigns, and the Grantor shall procure that all such successors and assigns shall execute such documents as may be reasonably required by the Royalty Holder to ensure that the Royalty shall so bind all such successors and assigns. (c) The Grantor agrees to pay the Royalty to the Royalty Holder in US Dollars each Quarter in accordance with the terms of this Agreement. (d) Notwithstanding that the Royalty has been granted by the Grantor, and without prejudice to any other obligation, MineCo will be jointly and severally liable for payment of the Royalty and any other amount due from the Grantor to the Royalty Holder.